Natera Signatera Predicts Chemotherapy Benefit in CRC Patients
AUSTIN, Texas, July 6, 2026 Natera, Inc. has announced the publication of groundbreaking clinical data in JAMA Oncology demonstrating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
AUSTIN, Texas, July 6, 2026 Natera, Inc. has announced the publication of groundbreaking clinical data in JAMA Oncology demonstrating...
CAMBRIDGE, United Kingdom, July 6, 2026 Astex Pharmaceuticals has entered into an exclusive worldwide research collaboration and license agreement...
